Thermo Fisher Acquires Solventum’s Purification Unit for $4.1 Billion

The deal strengthens Thermo Fisher’s bioproduction capabilities while helping Solventum address its financial challenges.

Thermo Fisher Scientific will purchase Solventum’s Purification & Filtration business for $4.1 billion in cash, with the transaction expected to close by the end of 2025.
Solventum plans to use the $3.4 billion in net proceeds primarily to reduce its $7.8 billion long-term debt and stabilize its financial position.
The purification business, which employs 2,500 people globally, generated approximately $1 billion in revenue in 2024 and complements Thermo Fisher’s bioproduction portfolio.
Thermo Fisher anticipates $125 million in annual operating income from revenue and cost synergies within five years of completing the acquisition.
Solventum, a recent spinoff from 3M, has been restructuring under a transformation plan that includes workforce reductions and strategic divestitures.